



SEQUENCE LISTING

Rodgers, Kathleen E.
diZerega, Gere S.

<120> Use of Angiotensin II Fragments and Analogs Thereof in Tissue Repair

<130> 00-1188-E1-A

<140> 10/667,066

<141> 2003-09-18

<150> 09/723,437

<151> 2000-11-28

<150> 09/608,532

<151> 2000-06-30

<150> 09/208,337

<151> 1998-12-09

<150> 08/465,775

<151> 1995-06-06

<150> 08/337,781

<151> 1994-11-14

<150> 08/126,368

<151> 1993-09-24

<160> 21

<170> PatentIn version 3.3

<210> 1

<211> 8

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide

<400> 1

Asp Arg Val Tyr Ile His Pro Phe
1 5

<210> 2

<211> 7

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide

<400> 2

Arg Val Tyr Ile His Pro Phe

1 5

<210> 3
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 3

Val Tyr Ile His Pro Phe
1 5

<210> 4
<211> 7
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 4

Asp Arg Val Tyr Ile His Pro
1 5

<210> 5
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 5

Arg Val Tyr Ile His Pro
1 5

<210> 6
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 6

Val Tyr Ile His Pro
1 5

<210> 7

<211> 4
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 7

Ile His Pro Phe
1

<210> 8
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 8

Asp Arg Val Tyr Ile His
1 5

<210> 9
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 9

Asp Arg Val Tyr Ile
1 5

<210> 10
<211> 4
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 10

Asp Arg Val Tyr
1

<210> 11
<211> 3
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 11

Asp Arg Val
1

<210> 12
<211> 3
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 12

His Pro Phe
1

<210> 13
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 13

Tyr Ile His Pro Phe
1 5

<210> 14
<211> 7
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is H, Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg, or D-Lys

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is Val, Ala, Leu, Ile, Gly, Pro, Aib, Acpc, or Tyr

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is Ile, Ala, Leu, Val, or Gly

<400> 14

Xaa Xaa Tyr Xaa His Pro Phe
1 5

<210> 15

<211> 8

<212> PRT

<213> Artificial

<220>

<223> Synthetic peptide

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa is Asp, Glu, Asn, Acpc, Ala, Me2Gly, Pro, Bet, Glu(NH2), Gly,
Asp(NH2), or Suc

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa is Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg, or D-Lys

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa is Val, Ala, Leu, Ile, Gly, Pro, Aib, Acpc, or Tyr

<220>

<221> MISC_FEATURE

<222> (4)..(4)

<223> Xaa is Tyr, Thr, Ser, or azaTyr

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> Xaa is Ile, Ala, Leu, Val, or Gly

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa is His or Arg

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa is Pro or Ala

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> Xaa is Phe, Phe(Br), Ile, or Tyr

<400> 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

1 5

<210> 16
<211> 7
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 16

Asp Arg Val Gly Gly Gly Gly
1 5

<210> 17
<211> 6
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 17

Gly Gly Gly Asp Arg Val
1 5

<210> 18
<211> 9
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 18

Arg Val Tyr Ile His Pro Lys Lys Lys
1 5

<210> 19
<211> 11
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<400> 19

Lys Lys Lys Lys Lys Arg Val Tyr Ile His Pro
1 5 10

<210> 20

<211> 5
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES /
<222> (1)..(1) /
<223> D-Ala

<400> 20

Ala Ile His Pro Phe
1 5

<210> 21
<211> 5
<212> PRT
<213> Artificial

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (5)..(5)
<223> D-Ala

<400> 21

Ile His Pro Phe Ala
1 5